Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers

 

NEW YORK, June 1, 2021 /PRNewswire/ -- Hoth Therapeutics (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline product, HT-KIT, a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis, on Thursday, June 3rd for interested shareholders. Dr. Glenn Cruse, Ph.D., Assistant Professor at North Carolina State University, who developed HT-KIT, will present the preclinical animal results that are part of the Company's ASCO Exhibition.

HT-KIT exhibited highly positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma. The anti-cancer therapeutic, which is currently in development, uses mRNA frame shifting that induces apoptosis of neoplastic mast cells. These findings show that the novel anti-cancer therapeutic rapidly induces apoptosis and cell death in neoplastic mast cells. Furthermore, systemic administration of the anti-cancer therapeutic in an in vivo humanized mast cell neoplasm model showed a significant reduction in tumors and neoplastic mast cell infiltration from the therapeutic group compared to the vehicle control group. There were no obvious signs of toxicity in the study animals, suggesting that the novel anti-cancer therapeutic was well-tolerated.

"Hoth Therapeutics is pleased to share greater details on the development of Dr. Glenn Cruse's HT-KIT and the potential it has to help alleviate pain for patients living with gastrointestinal stromal tumors, certain cancers and anaphylaxis," said Robb Knie, Chief Executive Office of Hoth Therapeutics, Inc. "Our company's focus remains on bringing innovative and novel therapeutics through development to address unmet patient needs and drive shareholder value."

Stefanie Johns, Ph.D., Chief Scientific Officer at Hoth Therapeutics, who works closely with the development of HT-KIT, will provide an overview on the science behind this novel therapeutic and how it helps to treat patients living with mast cell derived cancers and anaphylaxis. Stefanie will also provide a brief overview of the studies that are slated to initiate in Q2 2021.

This virtual presentation is open to shareholders and any parties interested in learning more about the development of HT-KIT for the treatment of mast cell derived cancers and anaphylaxis. Any questions for can be submitted in advance of the presentation by emailing questions to investorrelations@hoththerapeutics.com.

Meeting Details:
Date: Jun 3, 2021
Time: 1:00 PM ET
To receive the Zoom meeting details, please click the attached link to register for the event.

https://zoom.us/meeting/register/tJIsc-2uqDktEtJQUD7CrJjzUKJQWSAen7yH

After registering, you will receive a confirmation email containing information about joining the meeting.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.  To learn more, please visit https://ir.hoththerapeutics.com/.

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

Media Relations Contact:
Makovsky
Miriam Brito, Assistant Vice President
Email: hoth@makovsky.com
Phone: (914)-406-0435

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-plans-shareholder-presentation-on-ht-kit-therapeutics-preclinical-results-for-rare-cancers-301302677.html

SOURCE Hoth Therapeutics, Inc.

 
 
Company Codes: NASDAQ-NMS:HOTH
 

Back to news